Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Yoon, Harry H ^a   Orrock, Jared M ^a   Foster, Nathan R ^a   Sargent, Daniel J ^a   Smyrk, Thomas C ^a   Sinicrope, Frank A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL DENSITY; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; OVERALL SURVIVAL; QUANTITATIVE ANALYSIS; REGULATORY T LYMPHOCYTE; STROMA; SURVIVAL RATE; SURVIVAL TIME; TUMOR ASSOCIATED LEUKOCYTE;

BIOLOGICAL MARKERS; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; COLONIC NEOPLASMS; DNA MISMATCH REPAIR; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; LYMPHOCYTE COUNT; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; T-LYMPHOCYTES, REGULATORY;

EID: 84864692605     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042274     Document Type: Article

References (55)

1. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, et al. ((2006)) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960-1964.
2. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, et al. ((2005)) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353:2654-2666.
3. Guidoboni M, Gafa R, Viel A, Doglioni C, Russo A, et al. ((2001)) Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol 159:297-304.
4. Morishima N, Owaki T, Asakawa M, Kamiya S, Mizuguchi J, et al. ((2005)) Augmentation of effector CD8+ T cell generation with enhanced granzyme B expression by IL-27. J Immunol 175:1686-1693.
5. Pearce EL, Mullen AC, Martins GA, Krawczyk CM, Hutchins AS, et al. ((2003)) Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science 302:1041-1043.
6. Sinicrope FA, Rego RL, Garrity-Park MM, Foster NR, Sargent DJ, et al. ((2007)) Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability. Int J Cancer 120:1232-1238.
7. Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, et al. ((2010)) Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 222:350-366.
8. Salama P, Phillips M, Grieu F, Morris M, Zeps N, et al. ((2009)) Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 27:186-192.
9. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, et al. ((2005)) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 102:18538-18543.
10. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, et al. ((2007)) Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25:2586-2593.
11. Ladoire S, Martin F, Ghiringhelli F, ((2011)) Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother 60:909-918.
12. Phan V, Disis ML, ((2008)) Tumor stromal barriers to the success of adoptive T cell therapy. Cancer Immunol Immunother 57:281-283.
13. Chang LY, Lin YC, Mahalingam J, Huang CT, Chen TW, et al. ((2012)) Tumor-derived chemokine CCL5 enhances TGF-beta-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. Cancer research 72:1092-1102.
14. Frey DM, Droeser RA, Viehl CT, Zlobec I, Lugli A, et al. ((2010)) High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer 126:2635-2643.
15. Correale P, Rotundo MS, Del Vecchio MT, Remondo C, Migali C, et al. ((2010)) Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. Journal of immunotherapy 33:435-441.
16. Lee AM, Clear AJ, Calaminici M, Davies AJ, Jordan S, et al. ((2006)) Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 24:5052-5059.
17. Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, et al. ((2006)) Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 12:465-472.
18. Le Gouvello S, Bastuji-Garin S, Aloulou N, Mansour H, Chaumette MT, et al. ((2008)) High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 57:772-779.
19. Ling KL, Pratap SE, Bates GJ, Singh B, Mortensen NJ, et al. ((2007)) Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun 7:7.
20. Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, et al. ((2009)) Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 137:1270-1279.
21. Maul J, Loddenkemper C, Mundt P, Berg E, Giese T, et al. ((2005)) Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology 128:1868-1878.
22. Terzic J, Grivennikov S, Karin E, Karin M, ((2010)) Inflammation and colon cancer. Gastroenterology 138: 2101-2114 e2105.
23. Sinicrope FA, ((2010)) DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer. Nat Rev Clin Oncol 7:174-177.
24. Jass JR, ((2007)) Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50:113-130.
25. Ogino S, Nosho K, Irahara N, Meyerhardt JA, Baba Y, et al. ((2009)) Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 15:6412-6420.
26. Takemoto N, Konishi F, Yamashita K, Kojima M, Furukawa T, et al. ((2004)) The correlation of microsatellite instability and tumor-infiltrating lymphocytes in hereditary non-polyposis colorectal cancer (HNPCC) and sporadic colorectal cancers: the significance of different types of lymphocyte infiltration. Jpn J Clin Oncol 34:90-98.
27. Quinn E, Hawkins N, Yip YL, Suter C, Ward R, ((2003)) CD103+ intraepithelial lymphocytes-a unique population in microsatellite unstable sporadic colorectal cancer. Eur J Cancer 39:469-475.
28. Di Sabatino A, Ciccocioppo R, D'Alo S, Parroni R, Millimaggi D, et al. ((2001)) Intraepithelial and lamina propria lymphocytes show distinct patterns of apoptosis whereas both populations are active in Fas based cytotoxicity in coeliac disease. Gut 49:380-386.
29. Allegra CJ, Parr AL, Wold LE, Mahoney MR, Sargent DJ, et al. ((2002)) Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 20:1735-1743.
30. O'Connell MJ, Sargent DJ, Windschitl HE, Shepherd L, Mahoney MR, et al. ((2006)) Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer. Clin Colorectal Cancer 6:133-139.
31. Sinicrope FA, Rego RL, Okumura K, Foster NR, O'Connell MJ, et al. ((2008)) Prognostic impact of bim, puma, and noxa expression in human colon carcinomas. Clin Cancer Res 14:5810-5818.
32. Goode EL, Chenevix-Trench G, Hartmann LC, Fridley BL, Kalli KR, et al. ((2011)) Assessment of hepatocyte growth factor in ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev 20:1638-1648.
33. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, et al. ((2011)) Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29:1949-1955.
34. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, et al. ((2011)) Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 29:610-618.
35. Halling KC, French AJ, McDonnell SK, Burgart LJ, Schaid DJ, et al. ((1999)) Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 91:1295-1303.
36. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, et al. ((1998)) A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer research 58:5248-5257.
37. French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, et al. ((2008)) Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 14:3408-3415.
38. Hewish M, Lord CJ, Martin SA, Cunningham D, Ashworth A, ((2010)) Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol 7:197-208.
39. Erdman SE, Sohn JJ, Rao VP, Nambiar PR, Ge Z, et al. ((2005)) CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res 65:3998-4004.
40. Erdman SE, Rao VP, Olipitz W, Taylor CL, Jackson EA, et al. ((2010)) Unifying roles for regulatory T cells and inflammation in cancer. Int J Cancer 126:1651-1665.
41. Erdman SE, Rao VP, Poutahidis T, Ihrig MM, Ge Z, et al. ((2003)) CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res 63:6042-6050.
42. Zhang YL, Li J, Mo HY, Qiu F, Zheng LM, et al. ((2010)) Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways. Mol Cancer 9:4.
43. Hooper SJ, Wilson MJ, Crean SJ, ((2009)) Exploring the link between microorganisms and oral cancer: a systematic review of the literature. Head Neck 31:1228-1239.
44. Elpek KG, Lacelle C, Singh NP, Yolcu ES, Shirwan H, ((2007)) CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J Immunol 178:6840-6848.
45. Blatner NR, Bonertz A, Beckhove P, Cheon EC, Krantz SB, et al. ((2010)) In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proceedings of the National Academy of Sciences of the United States of America 107:6430-6435.
46. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, et al. ((2009)) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114:1141-1149.
47. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W, ((2009)) Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114:357-359.
48. Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, et al. ((2004)) Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21:589-601.
49. Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, et al. ((2008)) Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 112:2340-2352.
50. Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, et al. ((2002)) Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 99:2114-2121.
51. Banerjea A, Bustin SA, Dorudi S, ((2005)) The immunogenicity of colorectal cancers with high-degree microsatellite instability. World J Surg Oncol 3:26.
52. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, et al. ((2003)) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247-257.
53. Fontenot JD, Rudensky AY, ((2005)) A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 6:331-337.
54. Walker MR, Kasprowicz DJ, Gersuk VH, Benard A, Van Landeghen M, et al. ((2003)) Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest 112:1437-1443.
55. Baron U, Floess S, Wieczorek G, Baumann K, Grutzkau A, et al. ((2007)) DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol 37:2378-2389.